European Commission approves Roche’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
Posted:
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted marketing authorisation for Tecentriq® SC (atezolizumab), the European Union (EU)’s first PD-(L)1 cancer immunotherapy for subcutaneous (under the skin) injection.
According to the company, the design of the camera was developed to meet the needs of general healthcare providers, including primary care, optometry, retail health clinics and home health settings, and ensure accessibility and practicality in these environments.
Read more…
The NHS is to be allowed to hire physician associates (PA) from Ghana, Zimbabwe and Bangladesh, despite concerns over the quality of their training.
Doctors have been in revolt over the plan to increase the number of PAs and AAs…
Attendees
Sponsors and Exhibitors
AI Training for Doctors Workshops
Contact us